Sitting under the DePuy umbrella, Johnson & Johnson Medical Devices Companies has launched a new neurovascular business, to be called CERENOVUS.
Announced at the Society of NeuroInterventional Surgery (SNIS) 14th Annual Meeting, J&J’s new business will focus on delivering innovative therapies for hemorrhagic and ischemic stroke patients. In case you were wondering, Cerenovus derives from the Latin words for ‘new’ and ‘brain,’ which we’d obviously worked out.
So why the new focus? Globally, stroke is the second leading cause of death after the age of 60. The American Heart Association estimates someone dies of a stroke every 4 minutes. In the U.S. alone, the economic burden of stroke is estimated at $33 billion annually, which includes the cost of health care services, medications, and lost productivity. Unmet needs in this area is clearly where Cerenovus is being pitched. The company claims it is committed to changing the trajectory of stroke treatment.
Built on J&J’s pre-existing Codman Neuro infrastructure, the Cerenovus portfolio will include products from the recent acquisitions of Pulsar Vascular Inc., with a specialty in the endovascular treatment of wide-neck bifurcation aneurysms, and Neuravi Limited, offering extensive expertise and knowledge in acute ischemic stroke with its EmboTrap® Revascularization Platform.
“Our neurovascular business is evolving and CERENOVUS reflects our bold new vision, positioning and priorities,” said Shlomi Nachman, Company Group Chairman of Johnson & Johnson Medical Devices Cardiovascular & Specialty Solutions. “Inspired by how quickly a stroke can affect a person’s mind and our commitment to reducing the devastating impact, CERENOVUS aims to help physicians give stroke patients a new lease on life.”